Cargando…

Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis

BACKGROUND/AIMS: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. METHODS: We reviewed radiologically r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Min Sung, Lee, Hee Seung, Kang, Chang Moo, Lee, Woo Jung, Keum, Jiyoung, Sung, Min Je, Kim, Seung-seob, Park, Mi-Suk, Jo, Jung Hyun, Chung, Moon Jae, Park, Jeong Youp, Park, Seung Woo, Song, Si Young, Hwang, Ho Kyoung, Bang, Seungmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761915/
https://www.ncbi.nlm.nih.gov/pubmed/34140428
http://dx.doi.org/10.5009/gnl20301
_version_ 1784633642074505216
author Yoon, Min Sung
Lee, Hee Seung
Kang, Chang Moo
Lee, Woo Jung
Keum, Jiyoung
Sung, Min Je
Kim, Seung-seob
Park, Mi-Suk
Jo, Jung Hyun
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
Hwang, Ho Kyoung
Bang, Seungmin
author_facet Yoon, Min Sung
Lee, Hee Seung
Kang, Chang Moo
Lee, Woo Jung
Keum, Jiyoung
Sung, Min Je
Kim, Seung-seob
Park, Mi-Suk
Jo, Jung Hyun
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
Hwang, Ho Kyoung
Bang, Seungmin
author_sort Yoon, Min Sung
collection PubMed
description BACKGROUND/AIMS: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. METHODS: We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 13 propensity score matching (PSM) was performed to reduce selection bias. RESULTS: Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis. CONCLUSIONS: We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies.
format Online
Article
Text
id pubmed-8761915
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-87619152022-01-25 Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis Yoon, Min Sung Lee, Hee Seung Kang, Chang Moo Lee, Woo Jung Keum, Jiyoung Sung, Min Je Kim, Seung-seob Park, Mi-Suk Jo, Jung Hyun Chung, Moon Jae Park, Jeong Youp Park, Seung Woo Song, Si Young Hwang, Ho Kyoung Bang, Seungmin Gut Liver Original Article BACKGROUND/AIMS: Controversy regarding the effectiveness of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify the potential benefits of neoadjuvant therapy followed by surgery for resectable PDAC. METHODS: We reviewed radiologically resectable PDAC patients who received resection with curative intent at a tertiary hospital in South Korea between January 2012 and August 2019. A total of 202 patients underwent curative resection for resectable PDAC 167 underwent surgical resection first during this period, and 35 received neoadjuvant chemotherapy/chemoradiation therapy followed by surgery. Resectable PDAC patients were subdivided, and 13 propensity score matching (PSM) was performed to reduce selection bias. RESULTS: Compared with the group that received surgery first, the group that received neoadjuvant treatment followed by surgery had significantly smaller tumors (22.0 mm vs 27.0 mm, p=0.004), a smaller proportion of patients with postoperative pathologic T stage (p=0.026), a smaller proportion of patients with lymphovascular invasion (20.0% vs 40.7%, p=0.022), and a larger proportion of patients with negative resection margins (74.3% vs 51.5%, p=0.049). After PSM, the group that received neoadjuvant therapy had a significantly longer progression-free survival than those in the group that underwent surgery first (29.6 months vs 15.1 months, p=0.002). Overall survival was not significantly different between the two groups after PSM analysis. CONCLUSIONS: We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies. Editorial Office of Gut and Liver 2022-01-15 2021-06-22 /pmc/articles/PMC8761915/ /pubmed/34140428 http://dx.doi.org/10.5009/gnl20301 Text en Copyright © Gut and Liver. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yoon, Min Sung
Lee, Hee Seung
Kang, Chang Moo
Lee, Woo Jung
Keum, Jiyoung
Sung, Min Je
Kim, Seung-seob
Park, Mi-Suk
Jo, Jung Hyun
Chung, Moon Jae
Park, Jeong Youp
Park, Seung Woo
Song, Si Young
Hwang, Ho Kyoung
Bang, Seungmin
Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
title Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
title_full Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
title_fullStr Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
title_full_unstemmed Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
title_short Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis
title_sort response to neoadjuvant therapy and prognosis in patients with resectable pancreatic cancer: a propensity score matching analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761915/
https://www.ncbi.nlm.nih.gov/pubmed/34140428
http://dx.doi.org/10.5009/gnl20301
work_keys_str_mv AT yoonminsung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT leeheeseung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT kangchangmoo responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT leewoojung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT keumjiyoung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT sungminje responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT kimseungseob responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT parkmisuk responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT jojunghyun responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT chungmoonjae responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT parkjeongyoup responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT parkseungwoo responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT songsiyoung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT hwanghokyoung responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis
AT bangseungmin responsetoneoadjuvanttherapyandprognosisinpatientswithresectablepancreaticcancerapropensityscorematchinganalysis